Immuno-Oncology Attracts Big Deal Dollars For Biotechs
This article was originally published in Start Up
Executive Summary
Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.
You may also be interested in...
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.
Likelihood Of Approval Matters When Evaluating A Drug Development Partner
Despite having the lowest average likelihood of approval rating for US FDA regulatory decisions out of 18 disease groups, early-stage oncology deals continue to attract big price tags.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.